Eligard

DRUG3 trials

Sponsors

Astellas Pharma Europe Ltd., Institut Cancerologie de l'Ouest, McGill University Health Centre/Research Institute of the McGill University Health Centre

Conditions

Metastatic Prostate CancerProstate Cancer

Phase 2

Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer

CompletedNCT02274779

Institut Cancerologie de l'OuestProstate Cancer

Start: 2014-08-20End: 2024-07-22Updated: 2026-02-13

Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer

RecruitingNCT04249154

McGill University Health Centre/Research Institute of the McGill University Health CentreProstate Cancer

Start: 2019-09-03End: 2027-12-15Target: 77Updated: 2025-06-25

Phase 4

A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease

TerminatedNCT01933022

Astellas Pharma Europe Ltd.Metastatic Prostate Cancer

Start: 2014-08-31End: 2015-08-31Updated: 2017-03-09

Related Papers

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.

2020-09-1432 citations

Oligopelvis-GETUG P07: A multicenter phase II trial of combined salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses of prostate cancer.

Journal of Clinical Oncology2020-02-196 citations

OLIGOPELVIS – GETUG P07, a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer: Preplanned analysis of acute toxicity.

Journal of Clinical Oncology2016-01-10

OLIGOPELVIS – GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer

BMC Cancer2015-09-2545 citations